Welcome to LookChem.com Sign In|Join Free

CAS

  • or

86552-54-7

Phosphinic acid, (3-phenylpropyl)-, ethyl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

86552-54-7 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 86552-54-7 Structure

  • Basic information

    1. Product Name: Phosphinic acid, (3-phenylpropyl)-, ethyl ester
    2. Synonyms:
    3. CAS NO:86552-54-7
    4. Molecular Formula: C11H17O2P
    5. Molecular Weight: 212.229
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 86552-54-7.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: Phosphinic acid, (3-phenylpropyl)-, ethyl ester(CAS DataBase Reference)
    10. NIST Chemistry Reference: Phosphinic acid, (3-phenylpropyl)-, ethyl ester(86552-54-7)
    11. EPA Substance Registry System: Phosphinic acid, (3-phenylpropyl)-, ethyl ester(86552-54-7)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 86552-54-7(Hazardous Substances Data)

86552-54-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 86552-54-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,6,5,5 and 2 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 86552-54:
(7*8)+(6*6)+(5*5)+(4*5)+(3*2)+(2*5)+(1*4)=157
157 % 10 = 7
So 86552-54-7 is a valid CAS Registry Number.

86552-54-7Relevant articles and documents

NEW PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS, SUGAR ANALOGUES, AND COMPOSITIONS HAVING ANTI-CANCER ACTIVITY CONTAINING THE SAME

-

Page/Page column 29, (2009/03/07)

The invention provides new anticancer compounds of formula (1) such as defined in the present description. The invention also provides pharmaceutical compositions to be used in human or veterinary medicine, comprising at least one compound of formula (1). The present invention further relates to a compound of formula (1) such as defined in the present description, for use as a drug. The invention further relates to the use of a compound of formula (1) for manufacturing a human or animal anticancer pharmaceutical composition.

Palladium-catalyzed phosphorus-carbon bond formation: Cross-coupling reactions of alkyl phosphinates with aryl, heteroaryl, alkenyl, benzylic, and allylic halides and triflates

Bravo-Altamirano, Karla,Huang, Zhihong,Montchamp, Jean-Luc

, p. 6315 - 6329 (2007/10/03)

The direct formation of H-arylphosphinates and related compounds can be accomplished using palladium catalysis. This full paper examines the scope and some mechanistic aspects of this phosphorus-carbon bond forming reaction. The reactions of alkenyl and allylic halides are also described for the first time. This novel cross-coupling provides a convenient access to a variety of substituted H-phosphinates.

New serine protease inhibitors with leukotriene B4 (LTB4) receptor binding affinity

Nakayama, Yoshisuke,Senokuchi, Kazuhiko,Sakaki, Katsuhito,Kato, Masashi,Maruyama, Toru,Miyazaki, Toru,Ito, Hidenori,Nakai, Hisao,Kawamura, Masanori

, p. 971 - 985 (2007/10/03)

A series of new trypsin-like serine protease inhibitors, 1, 2 and 7-23, containing amidinobenzene moiety was found to show potent LTB4-receptor affinity. Among them, compounds 1 and 2 were found to be LTB4 receptor antagonists based on an inhibition assay of human polymorphonuclear neutrophil (PMN) intracellular calcium mobilization induced by LTB4. Compounds 1 and 2, which satisfy the reported structural requirements for good oral activity, are expected to show a balanced dual mode of action, i.e., protease inhibitory activity and LTB4 receptor antagonist activity, in vivo.

PHOSPHONAMIDATE COMPOUNDS

-

, (2008/06/13)

Phosphonamidates of the formula STR1 wherein X is a substituted or unsubstituted imino or amino acid or ester. These compounds possess angiotensin converting enzyme activity and are thus useful as hypotensive agents.

Phosphonamidate compounds

-

, (2008/06/13)

Phosphonamidates of the formula STR1 wherein X is an amino acid or ester. These compounds possess angiotensin converting enzyme inhibition activity and enkephalinase inhibition activity. Thus they are useful as hypotensive and analgesic agents.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 86552-54-7